Cargando…

Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2

Arginases are often overexpressed in human diseases, and they are an important target for developing anti-aging and antineoplastic drugs. Arginase type 1 (ARG1) is a cytosolic enzyme, and arginase type 2 (ARG2) is a mitochondrial one. In this study, a dataset containing 2115-FDA-approved drug molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Detroja, Trishna Saha, Samson, Abraham O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416497/ https://www.ncbi.nlm.nih.gov/pubmed/36014374 http://dx.doi.org/10.3390/molecules27165134

Ejemplares similares

Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine
por: Saha Detroja, Trishna, et al.
Publicado: (2022)

Text-Mining Approach to Identify Hub Genes of Cancer Metastasis and Potential Drug Repurposing to Target Them
por: Detroja, Trishna Saha, et al.
Publicado: (2022)

Virtual Screening of FDA-Approved Drugs for Enhanced Binding with Mitochondrial Aldehyde Dehydrogenase
por: Zhou, Boqian, et al.
Publicado: (2022)

Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Gu, Shuo, et al.
Publicado: (2018)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Fully automated virtual screening pipeline of FDA-approved drugs using Caver Web
por: Musil, Milos, et al.
Publicado: (2022)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Virtual Screening of FDA-Approved Drugs against LasR of Pseudomonas aeruginosa for Antibiofilm Potential
por: Sadiq, Suhaib, et al.
Publicado: (2020)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
por: Liang, Hualou, et al.
Publicado: (2021)

Identification of FDA Approved Antiviral Drugs for COVID-19 Treatment using Unbiased Virtual Screening
por: Greer, Rory, et al.
Publicado: (2021)

Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
por: Afzaal, Hasan, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy
por: Shahab, Muhammad, et al.
Publicado: (2023)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020)

Network model‐based screen for FDA‐approved drugs affecting cardiac fibrosis
por: Zeigler, Angela C., et al.
Publicado: (2021)

Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study
por: Srivastava, Varshita, et al.
Publicado: (2023)

A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
por: Ekins, Sean, et al.
Publicado: (2014)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
por: Amen, Triana, et al.
Publicado: (2016)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
por: Mellini, Marta, et al.
Publicado: (2019)

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
por: Caly, Leon, et al.
Publicado: (2020)

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_onrpnipqfrlnsilq2g9e0rjkpk